Personalized leukemia vaccine aims to outsmart relapse
NCT ID NCT01096602
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This study tests a personalized vaccine made from a patient's own leukemia cells fused with immune cells, combined with a drug that blocks PD-1, to help the immune system recognize and destroy any remaining leukemia cells after chemotherapy. The goal is to prevent the cancer from coming back. Adults with acute myeloid leukemia who have achieved remission after chemotherapy are eligible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a dendritic cell vaccine made from the patient's own leukemia cells fused with immune cells, given alongside a PD-1 blocking agent
- What this could lead to
- If successful, this approach could help prevent AML from returning after chemotherapy, potentially leading to long-term remission or a functional cure.
- What could go wrong
- This is a mid-stage trial with a small number of participants, so results may not apply to all patients. The vaccine can cause side effects, and it is not yet proven to prevent relapse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pressurized oxygen boost cord blood transplants?
- Supercharged donor cells aim to stop leukemia return after transplant
- Artificial intelligence could help prevent transplant complications by personalizing drug dosing
- New transplant recipe aims to tame Graft-Versus-Host disease
- New drug targets genetic weakness in Hard-to-Treat blood cancers
- New drug aims to wake up immune system against Hard-to-Treat leukemia